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Signal transducer and activator of transcription-3 (Stat3) was studied along with several steps of the PI3/Akt pathway in a series of
64 gliomas that included both malignant and low-grade tumors, using quantitative immunohistochemistry, Western blotting, and
molecular biology techniques. The goal of the study was to investigate whether activated Stat3 (phospho-Stat3) levels correlated
with cell proliferation, apoptosis, and autophagy. Stat3 and activated Akt (phospho-Akt) expression increased with malignancy
grade, but did not correlate with proliferation and survival within the category of glioblastomas. A correlation of Stat3 with Akt
was found, indicating a regulation of the former by the PI3/Akt pathway, which, in turn, was in relation with EGFR ampliﬁcation.
Stat3 and Akt did not show any correlation with apoptosis, whereas they showed an inverse correlation with Beclin 1, a stimulator
of autophagy, which was rarely positive in glioblastomas. Autophagy seems then to be inactivated in malignant gliomas.
Copyright © 2008 Valentina Caldera et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Stat3 is a member of a family of latent transcription factors
that transduce extra-cellular signals, such as those mediated
by cytokines and growth factors [1]. Stat3 is activated by
the phosphorylation of a tyrosine residue (phospho-Stat3),
which leads to its dimerization and nuclear translocation. It
transcriptionally regulates the expression of genes responsi-
ble for proliferation and survival. pStat3 has been shown to
suppress apoptosis in many cancers [2, 3].
pStat3 is ubiquitously expressed in mammalian cells and
is constitutively activated in glioblastomas by IL-6 [4]. It has
been shown that in many cancers when pStat3 is inhibited,
its target genes, Bcl-XL, c-myc, and Cyclin D1, are down-
regulated, and cells undergo apoptosis [3, 5, 6].
pStat3 is not detected in normal brain tissue. It is
activated by aberrant EGFR signaling and IL-6 in malignant
gliomas [7], and it may be a rational therapeutic target;
WP10066, similar to AG490, has been shown to inhibit
pStat3 and to induce apoptosis in vitro and in vivo [8]. A
pStat3 mutant can induce cellular transformation and tumor
formation in nude mice by binding DNA and activating
transcription [5], and inhibition of pStat3 may promote the
eﬃcacy of immunotherapy [9]. In a series of diﬀuse gliomas,
pStat3 has been found to be focally expressed in less than
9% of gliomas [10]. However, in another series, it was highly
expressed at almost equal levels in anaplastic astrocytomas
and glioblastomas (55.6% versus 56.4%), together with
pAkt, and its expression also correlated with EGFR status
(EGFRvIII), but had no predictive value [11]. pStat3 was
found to be positive in 40% of gliomas and correlated with
histological grades [12]. Recently, it has been demonstrated
that both inhibitors of the PI3/Akt pathway [13] and pStat3
can induce autophagy in glioma cells [14].
Autophagy is a caspase-independent process of degrada-
tion, characterized by the formation of autophagosomes and
their fusion with lysosomes [15]. It is regulated by pmTOR
anditscomplexes[16],byautophagygenes(ATG)andBeclin2 Journal of Oncology
1[ 17]. Beclin 1 is also known as Atg6, and is a component of
a complex that includes the class III phosphatidylinositol-3-
kinase and is an autophagic stimulator [16].
Quantitative evaluation of pStat3 expression in gliomas
is diﬃcult due to the regional heterogeneity of its expression.
We investigated pStat3 expression and its correlations with
histologicalgrade,EGFRaberrations,PTENmutations,pAkt
expression, cell proliferation, and apoptosis/autophagy in a
series of gliomas.
2.MaterialsandMethods
Surgical samples were collected from the Department of
Neuroscience, University of Turin, and from the Clinical
and Experimental Medical Department of East Piedmont,
University of Novara. Sixty four gliomas were studied: 34
glioblastomas (GBMs), 10 grade III anaplastic astrocytomas,
10 grade II astrocytomas, and 10 oligodendrogliomas (5
grade II and 5 grade III), diagnosed according to the WHO.
Allthetumorsampleswerefromﬁrstsurgerywithpartial
or total removal. No recurrence and no second-operation
materials were studied.
Surgical samples were ﬁxed in buﬀered formalin, embed-
ded in paraﬃn and cut in 5-micron thick serial sections.
2.1. DNA Extraction. Genomic DNA was extracted from
the 34 formalin-ﬁxed, paraﬃn-embedded GBM samples
according to a standard phenol-chlorophorm protocol. Only
proliferating areas were selected.
2.2. EGFR (Epidermal Growth Factor Receptor) Ampliﬁca-
tion. EGFR ampliﬁcation status was assessed as previously
described [18]. Fluorescent PCR products were analyzed by
capillary electrophoresis on an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA). The
ampliﬁcation status of the EGFR gene was determined by
measuring the EGFR/INF-γ ratio: a ratio >2.09 was taken as
evidence of more than two copies of the EGFR gene.
2.3. PTEN (Phosphatase and Tensin Homolog) Mutation
Analysis. The PTEN gene was ampliﬁed as ten polymerase
chain reaction (PCR) fragments covering the 9 exons and at
least 50 bp of ﬂanking intronic sequence.
Allthefragmentswereampliﬁedusingthesameprotocol;
an initial denaturation at 96◦C for 10 minutes followed by
94◦C for 30 seconds, 58◦C for 30 seconds, and 72◦Cf o r3 0
seconds, for 33 cycles. A ﬁnal elongation step of 10 minutes
at 72◦C was added. The reactions were performed in a total
volume of 25μL containing 50mM KCl, 10mM Tris-HCl
(pH 8.3), 1.5mM MgCl2, 250μM of each dNTP, 1 unit of
Taq Gold polymerase (Applied Biosystems), 10pmol of each
primer and 100ng of genomic DNA. Primer sequences are
available upon request.
Prior to sequencing, unincorporated dNTPs and primers
were removed by using MultiScreen PCR ﬁlter plates on a
MultiScreenHTS vacuum manifold (Millipore, MA Billerica,
USA).
Each PCR product was further analyzed by direct DNA
sequencing in both directions on an ABI PRISM 3100
Genetic Analyzer using the BigDye Terminator version 1.1
cycle sequencing Kit.
2.4. Immunohistochemistry (IHC). The following primary
antibodies were used. Mouse monoclonal antiphospho-Stat3
(Tyr705), diluted 1:40 (#9138, Cell Signaling Technology,
Beverly, MA, USA); mouse monoclonal antiphospho-Akt
(Ser473), diluted 1:100 (#4051, Cell Signaling Technology);
rabbit polyclonal anti-EGFRwt, diluted 1:50 (#2232, Cell
Signaling Technology); rabbit polyclonal anti-EGFRvIII,
diluted 1:50 (SC1031, GenScript Corporation, Piscataway,
NJ, USA); mouse monoclonal anti-PTEN (A2B1), diluted
1:1000 (sc-7974, Santa Cruz Biotechnology, Santa Cruz, CA,
USA); mouse monoclonal anti-Ki-67/MIB.1, diluted 1:100
(M7240, Dako, Carpinteria, CA, USA); rabbit polyclonal
anti-Caspase-3, diluted 1:20 (AB3623, Chemicon Interna-
tional Inc., Temecula, CA, USA); rabbit polyclonal anti-
PARP1, diluted 1:200 (#9542, Cell Signaling Technology);
rabbit polyclonal anticleaved PARP1 (Asp214), diluted 1:50
(#9541, Cell Signaling Technology), rabbit polyclonal anti-
Beclin 1, diluted 1:200 (sc-11417, Santa Cruz Biotechnol-
ogy).
Besides the H&E method, immunohistochemistry was
performed on consecutive sections using a standard
streptavidin-biotin system (Dako) with diaminobenzidine as
the substrate (DAB, Roche Diagnostics GmbH, Penzberg,
Germany), and the sections werecounterstained with Harris’
hematoxylin. Antigen retrieval was performed by microwav-
ing the sections in 0.01M citrate buﬀer (pH 6.0 or 7.4) (3×3
minutes at 600W). Negative controls were only incubated
with the secondary antibody. The positive controls were
humanbreastcancersamplesforpStat3andpAkt,malignant
neuroblastoma for Caspase-3, PARP1 and cleaved-PARP1,
and a glioblastoma sample with no mutations for PTEN. A
primary human glioblastoma with EGFR gene ampliﬁcation
was used as a positive control for the wild type EGFR
(EGFRwt).
2.5.EvaluationofImmunohistochemicalStaining. Inallofthe
samples, only the proliferating areas were evaluated, while
necrotic or regressive areas were excluded from analysis.
Antigen expression was evaluated according to the intensity
(–, +, ++), frequency of positive nuclei/cells (<20%, 20%–
50%, >50%), and distribution (focal or diﬀuse), with a
scoring system that used three categories A, B, and C
(Table 1).
The Labelling Index (LI) was calculated as the mean of
the areas, of at least 1000 cells. Visual analysis was used
to identify the areas with the highest frequency of positive
nuclei/cytoplasms. These areas were usually 5 HPF with
immersion oil, which corresponded to 0.001mm2.
In GBMs only, Caspase-3 and cleaved-PARP1
expression was calculated as the percentage of positive
nuclei/cytoplasms after counting all of the tumor sections.
In addition, in GBMs, the Ki-67/MIB.1 LI was calculated
also in areas that showed the maximum pStat3 LI , and theJournal of Oncology 3
Table 1: Scoring system for evaluation of immunostaining.
Marker Category
AB C
pStat3 and pAkt Diﬀuse, <20%, + with or without foci Diﬀuse, 20–50%, ++ with or
without foci
Diﬀuse, >50% or >20%, +++ with
multiple foci
Ki-67/MIB.1 <20% 20–30% >30%
EGFR Ampliﬁcation Non-ampliﬁed Non-ampliﬁed More than 2 copies
EGFRwt − +/− +
EGFRvIII − +/− +
PTEN Positive — Negative
Diﬀuse = homogeneous distribution of positive nuclei.
Foci = circumscribed small areas with a higher percentage of positive nuclei.
% = number of positive nuclei × 100 nuclei.
pStat3 LI was calculated in the areas with the maximum Ki-
67/MIB.1 LI.
2.6.ProteinExtractionandWesternBlottingAnalysis. Paraﬃn
sections for protein extraction were deparaﬃnized and
homogenized in RIPA buﬀer with a protease inhibitor
cocktail (Sigma Aldrich Co., St. Louis, MO, USA). After
quantiﬁcation of the total protein lysate using the BCA
Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA),
80μg of total protein was resolved by SDS-PAGE on a
12% gel. The proteins were then transferred to nitro-
cellulose membranes (Biorad, Hercules, CA, USA). Blots
were incubated overnight at 4◦C with a rabbit monoclonal
antiphospho-Akt (Ser473) antibody at a dilution of 1:1000
(#3787, Cell Signaling Technology), and they were then
incubated with the appropriate HRP-conjugated secondary
antibody(Dako).ProteinsignalsweredetectedusingtheECL
detection system (GE Healthcare, Buckinghamshire, UK). A
speciﬁc anti-β-actin antibody (A5441, Sigma Aldrich Co.)
was used to normalize sample loading and transfer. The
intensity of the bands was quantiﬁed by densitometry using
the NIH Image J software (RSB, NIMH, Bethesda, MD,
USA).
2.7. Statistical Analysis. Associations between the variables
were evaluated using 2 × 2 contingency tables and the two-
tailed Fisher’s exact test. Correlation analyses were per-
formed using the Pearson’s correlation coeﬃcient. Survival
analysis was carried out using the Kaplan-Meier method
(SPSS version 15.0, Chicago, IL, USA).
3. Results
3.1. EGFR Ampliﬁcation and Immunohistochemistry (Per-
formed Only in GBMs). Twelve out of 34 GBMs showed
EGFR ampliﬁcation (35.3%), and 22 of the GBMs were
immunopositive for EGFRwt (64.7%). All but one of the 12
cases that carried EGFR ampliﬁcation were immunopositive
for EGFRwt (P = .239). Out of the 22 cases that did not have
EGFR ampliﬁcation, 11 were immunopositive for EGFRwt
(score B + C).
Out of the 12 cases with EGFR ampliﬁcation, six were
positive for EGFRvIII (50%) (P = .0403), whereas out of the
22 cases without ampliﬁcation, only three were positive for
EGFRvIII (13.6%) (Table 2). Immunostaining for EGFRwt
was either moderate or intense in most of the cells analyzed
(Figure 1(a)). Immunostaining for EGFRvIII was moderate,
and showed greater regional variability than the EGFRwt
immunostaining (Figure 1(b)).
Our cases of glioblastoma were at their ﬁrst surgery
and none derived from a previous astrocytoma. However,
a distinction between primary and secondary glioblastoma
was not made, also because the only EGFR ampliﬁcation is
not an absolute criterium.
3.2. PTEN Mutation Analysis and Immunohistochemistry
(Performed Only in GBMs). All the coding region and the
intron-exon boundaries of the PTEN gene were ampliﬁed in
ten diﬀerent PCR fragments in the 34 GBM cases.
Direct sequencing led to the identiﬁcation of four diﬀer-
ent single nucleotide variations, located in the coding region
(n = 1) and introns (n = 3), respectively. These variations
wereobservedinthefourpatientsresultednegativeforPTEN
expression by immunohistochemistry.
Variation in the coding region is a non-synonymous
substitution c.389G→A leading to an amino acid substi-
tution at codon 130 (Arg130Gln), previously conﬁrmed as
somatic variant in high-grade gliomas and in gliosarcomas
[19, 20]. Among the three intronic variations, one is a
new sequence variation, namely IVS8+36C/T; the remain-
ing were IVS8+32T/G and IVS1−97A/G, corresponding to
validated SNPs in public database of single nucleotide poly-
morphisms (http://www.ncbi.nlm.nih.gov/SNP/) (rs555895
and rs1903858, resp.) (Figure 2). The position of the
intronic variations is relative to the ﬁrst (+1) or the
last (−1) nucleotide of each intron (Gene Bank sequence
NM 000314).
Thirty out of the 34GBMs were immunopositive for
PTEN (88.2%). The staining intensity was strong and uni-
forminallofthecases.Reactiveastrocyteswereimmunopos-
itive for PTEN, and this staining was also seen in the
four tumors that were negative for PTEN immunostaining
(Figure 1(c)).4 Journal of Oncology
Table 2: Correlation of EGFR gene ampliﬁcation status with EGFRwt and EGFRvIII immunohistochemistry in 34 glioblastomas.
EGFR ampliﬁcation EGFRwt (B + C) immunohistochemistry P value EGFRvIII (B + C) immunohistochemistry P value
Positive (n = 22) Negative (n = 12) Positive (n = 9) Negative (n = 25)
Positive 12 (35.3%) 11 (91.7%) 1 (8.3%) .0239 6 (50.0%) 6 (50.0%) .0403
Negative 22 (64.7%) 11 (50.0%) 11 (50.0%) 3 (13.6%) 19 (86.4%)
(a) (b) (c)
(d) (e) (f)
Figure 1: (a) Positive cells for EGFRwt, GBM. (b) Positive cells for EGFRvIII, GBM. (c) PTEN positive staining, GBM. (d) Ki-67/MIB.1 high
number of positive nuclei, GBM. (e) pStat3 positive nuclei in GBM. (f) pStat3 negative nuclei in grade II oligodendroglioma. DAB, 400×.
G       G          A     C      N       A       A      C       T
(a)
G        G         A     C      G       A        A      C       T
(b)
Figure 2: Nucleotide sequence analysis of PTEN exon 5. (a) The nonsynonymous substitution (Arg130Gln, CGA > CAA) from the tumor
DNA of Case 6463. (b) The wild-type exon 5 sequence from normal control DNA.Journal of Oncology 5
(a) (b) (c)
(d) (e) (f)
Figure 3:(a)PositivecytoplasmicstainingforpAkt,GBM.(b)PositivenuclearstainingforpAktingradeIIIoligodendroglioma.(c)Caspase-
3 positive nucleus, GBM. (d) Beclin 1 positive cytoplasmic and nuclear staining, GBM. (e) PARP1 positive nuclei, GBM. (f) Cleaved-PARP1
positive nucleus, GBM. DAB, 400×.
3.3. Ki-67/MIB.1. T h eL Iw a s5 %( 2 – 6 % )f o rg r a d eI I
astrocytomas, 12% (5–20%) for grade III astrocytomas, 2%
(0–10%)forgradeIIoligodendrogliomas,15%(12–28%)for
grade III oligodendrogliomas, and 23% (12–30%) for GBMs
(Figure 1(d)).
3.4. Phospho-Stat3 Immunohistochemistry. pStat3 immunos-
taining was scored as “A” in almost all of the grade II
astrocytomas and oligodendrogliomas, as “B” in the grade
III astrocytomas and oligodendrogliomas, and as “B” or “C”
in GBMs. The pStat3 staining was mainly nuclear, with the
exception of few scattered areas where it was cytoplasmic
(Figure 1(e)). Cases with positivity <20% were considered as
negative.Thepercentagesofpositive cellswere0%,50%,and
56.2% for grade II, III astrocytomas and GBMs, respectively.
In oligodendrogliomas, the values were 0% and 20% for
grade II and III, respectively (Figure 1(f)).
3.5. Phospho-Akt Immunohistochemistry. In grade II astro-
cytomas and oligodendrogliomas, the staining was mostly
nuclear and was scored as “A”. In grade III astrocytomas
and oligodendrogliomas, the staining was still nuclear and
was scored as “A”. In GBMs, the staining was mainly
cytoplasmic, and only occasionally nuclear, and was scored
as “C” (Figure 3(a)). In GBMs microvascular proliferations
were negative and occasionally the staining was more
intense in cells around vessels and outside pseudopalisades.
The frequency values were 0%, 20%, and 80% for grade
II, III astrocytomas and GBMs, respectively. In oligoden-
drogliomas, the values were 0% and 20% for grade II and
III, respectively (Figure 3(b)).
3.6.Phospho-AktWesternBlotting(PerformedOnlyinGBMs).
TheWesternblottinganalysisshowedvariablypositivebands
(Figures 4(a)-4(b)).
3.7. Caspase-3, PARP1, and Cleaved-PARP1 Immunohisto-
chemistry(PerformedOnlyinGBMs). Caspase-3waspositive
as cytoplasmic or nuclear staining or in apoptotic bodies
(Figure 3(c)). PARP1 was positive in all the nuclei of
the tumor (Figure 3(e)). Cleaved-PARP1 was occasionally
positive in nuclei and distributed as Caspase-3 (Figure 3(f)).
Theywereveryrareinproliferatingareasandmoreabundant
in perinecrotic palisades, which were not counted in this
work. The percentages of positive cell/nuclei were constantly
<0.02.
3.8. Beclin 1 Immunohistochemistry (Performed Only in
GBMs). Beclin 1 was positive in two cases only. The staining
was both nuclear and cytoplasmic (Figure 3(d)).
3.9.CorrelationAnalysis. pStat3andpAktLIscorrelatedwith
the three histological grades (Table 3), but not with survival
or with Ki-67/MIB.1 LI within the glioblastoma category. A
correlation of pStat3 LI with Ki-67/MIB.1 LI was not found
either comparing the mean LI values or the frequency peaks.6 Journal of Oncology
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Figure 4: (a) Western blotting of pAkt expression. Positive bands in a sample of 8 cases. (b) Quantitative analysis of pAkt levels normalized
to β-actin data.
Also pAkt LI did not correlate with Ki-67/MIB.1 LI. There
was a correlation between EGFR ampliﬁcation status and
EGFRwt and EGFRvIII immunohistochemistry (P = .0239
and P = .0403, resp.), considering scores B + C, but not
between EGFRwt and EGFRvIII immunohistochemistry
(Table 2). EGFR ampliﬁcation and immunohistochemistry
did not correlate with pStat3. In contrast, correlations were
found between EGFRwt immunostaining and levels of pAkt
by Western blotting (P = .010), between the pAkt levels
by Western blotting and immunohistochemistry (r = 0.53,
P = .0348), and the pAkt levels by Western blotting and
pStat3 LI by immunohistochemistry (r = 0.473, P = .0146)
(Table 4). The number of cases with positive Beclin 1 was too
few, that is, the opposite with the number of cases positive
for pStat3, pAkt and Ki-67/MIB.1 LIs in glioblastomas.
The values of Caspase-3 and cleaved-PARP1 LIs were
so low as to make the correlation study with the antigens
studied be ineﬀective.
In glioblastomas, no correlation between pStat3, pAkt,
Ki-67/MIB.1 LIs and survival was found by Kaplan-Meier
analysis.
4. Discussion
Demonstration of pStat3 expression in gliomas using
immunohistochemistry is not an easy task, especially when
attempting to quantitatively evaluate it, due to its heteroge-
neous expression, which is particularly evident in malignant
gliomas. It has been emphasized that this is particularly
important in microarray-based studies, since it is crucial that
thefociexamined arerepresentative oftheentire tumor[10].
Heterogeneity in expression can lead to bias when evaluating
many antigens in malignant gliomas. There have been
attempts to overcome this limitation by the introduction of
sophisticated procedures to evaluate positive cells or nuclei
when performing immunohistochemical analysis. We used a
double-check procedure, and examined antigen expression
in full-size tissue sections and in foci with the highest LI
values.
In systemic tumors, it has been debated whether pStat3
levels correlate with a worse or a better prognosis, as it
h a sb e e no b s e r v e di nb r e a s tc a n c e r[ 21]. In our series,
pStat3 expression is of moderate intensity, has a nuclear
location and its LI signiﬁcantly increases with malignancy.
In glioblastomas, the LI reaches 56.2%, which is less than the
values observed in previous studies [7], but is similar to the
v a l u e st h a th a v eb e e nr e p o r t e di nm o r er e c e n ts t u d i e s[ 11].
As pStat3 is involved in the transformation process, it should
have a predictive role for the whole group of astrocytic
gliomas, and our results conﬁrm that it does have prognostic
signiﬁcance whencomparing the three grades of malignancy.
However, pStat3 was not shown to be predictive within the
group of malignant gliomas, as it was observed in a previous
study [11]. No correlation was found between pStat3 and Ki-
67/MIB.1LIinglioblastomas.Thelackofapredictiverolefor
pStat3 in glioblastomas is consistent with observations that
manyotherphenotypicfeaturesdonothavepredictivevalue.
The prognostic role of Ki-67/MIB.1 LI itself in glioblastomas
has also been the subject of discussion, and we believe that it
is not predictive [22]. Our results are not entirely surprising,
since the relationship between pStat3 and proliferation is
rather indirect, and is mediated through the inhibition of
apoptosis by the activation of the Bcl-2 family [23].
pStat3 inhibition has been shown to have a number of
anticancer eﬀects. pStat3 upregulates the transcription of
several genes that control tumor cell survival, resistance to
apoptosis, cell cycle progression and angiogenesis [3, 5, 6,
23–25], and pStat3 inhibition speciﬁcally induces apoptosis
[3, 4, 8, 26].
We found a correlation between EGFR ampliﬁcation and
EGFRwt and EGFRvIII immunostaining in our samples.
Only one case with an EGFR ampliﬁcation was negative
for EGFR immunohistochemistry, whereas 50% of the
cases without EGFR ampliﬁcation were positive for EGFR
immunohistochemistry, and 50% of the cases with EGFR
ampliﬁcation expressed EGFRvIII, in contrast to 13.6%
of the cases without ampliﬁcation. Some of these results
are consistent with previous observations [11]. An early
hypothesis suggested that pStat3 is activated by deregulation
of EGFR and aberrant IL-6 expression [4]. In gliomas,
it was observed that the levels of pStat3, together with
pAkt, correlate with EGFR aberrations, but speciﬁcally withJournal of Oncology 7
Table 3: Immunohistochemical frequencies in the three glioma grades.
Activated pathway Astrocytoma (n = 20) GBM (n = 34) Oligodendroglioma (n = 10)
Grade II Grade III Grade IV Grade II Grade III
Stat3 0% 50% 56.2% 0% 20%
Akt 0% 20% 80% 0% 20%
Table 4: Correlation of EGFR ampliﬁcation, EGFRwt and EGFRvIII immunopositivity with pAkt and pStat3 immunohistochemistry.
Activated pathway EGFR ampliﬁcation P value
Positive (n = 12) Negative (n = 22)
Akt IHC 3 (25.0%) 8 (36.4%) ns
Akt WB∗ 5 (41.7%) 9 (41%) ns
Stat3 6 (50.0%) 8 (31.8%) ns
EGFRwt (B + C) Immunohistochemistry
Positive (n = 22) Negative (n = 12)
Akt IHC 7 (31.8%) 4 (33.3%) ns
Akt WB∗ 12 (67%) 2 (12%) .010
Stat3 9 (40.90%) 5 (41.6%) ns
EGFRvIII (B + C) Immunohistochemistry
Positive (n = 9) Negative (n = 25)
Akt IHC 3 (33.3%) 8 (32.0%) ns
Akt WB∗ 3 (33%) 11 (44%) ns
Stat3 5 (55.5%) 9 (36.0%) ns
ns = not signiﬁcative.
∗Only WB values >0.4 were considered.
EGFRvIII expression [11]. We did not ﬁnd any correlation
between pStat3 LI and EGFR status. We can only point out
that the P value of EGFR ampliﬁcation when compared
with pStat3 LI was the lowest of the other nonsigniﬁcant
comparisons. However, it cannot be ruled out that the small
number of samples in our study may have prevented us from
ﬁnding a potential correlation between pStat3 and EGFR
ampliﬁcation,particularlyaspAktlev elscorrelatewithEGFR
in a Western blotting analysis. This can be worth also for
the lack of correlation between EGFR status and pStat3 by
immunohistochemistry. It is to be considered that only four
cases of GBMs showed negative PTEN expression, and only
one had a real mutation. Anyway, all the four cases without
PTEN expression showed already EGFR ampliﬁcation, with
the exception of the only case with a real PTEN mutation.
The impossibility to ﬁnd any correlation of pStat3
expression with the apoptotic index was due to the short
durationofthiseventandtothetoolownumberofapoptotic
nuclei found in proliferating tumor areas, which can be
related to the diﬀerent pathways leading to apoptosis. The
action of pStat3, via the Bcl-2 family [5, 23], may lead to the
inhibition of transcriptional or intrinsic apoptosis pathway,
and may not aﬀect receptor-mediated or extrinsic apoptosis
pathway, which may be the major one in perinecrotic tumor
areas [27]. The selection of only proliferating areas in our
study, and the exclusion of regressive and necrotic ones,
may have eliminated the major sources of apoptosis. There
is cross-talk between the intrinsic and extrinsic pathway to
apoptosis by BH3-interacting domain death agonist (BID)
[28]. However, the low detectable values of Caspase-8 in
the receptorial pathway to apoptosis in gliomas [29], would
make pointless this cross-talk.
Even considering that PTEN was mutated only in one
case of our series, no correlation was found between pAkt
LI and Ki-67/MIB.1 LI. The levels of pAkt correlate with
malignancy within the three grades in our experiments
and in other reports [30], but in glioblastomas there is no
correlation with the proliferation marker. The explanation
can be the same given before for pStat3.
The localization of pStat3 is not so clear-cut in the
various observations. It was also shown to be predominantly
localized in endothelial cells [31], or in tumor and in
endothelial cells [7]. Activated Stat3alpha found in brain
tumors was thought to be the result from the action of the
endothelial tyrosine kinase VEGFR-2, which plays a central
role in autocrine VEGF activation [31]. We found occasional
endothelial cells in vascular proliferations of GBMs that
stained positive for pStat3, but we could not correlate them
with other features of the tumors.
ThecorrelationofpStat3withpAktfoundbyusconﬁrms
previous observations [11], and emphasizes the position of
pStat3 downstream pAkt in the PI3K/Akt signalling pathway
[32]. Finally, Beclin 1 was found to be positive in two cases
only of glioblastomas, with an inverse correlation with pAkt
and pStat3. Beclin 1 is considered to be representative of
the type II programmed cell death, or autophagy, and in
cancers this pathway is not clearly separated from type I
programmed cell death, or apoptosis, and both pathways can8 Journal of Oncology
be functional in the same cell [33]. In many malignancies,
Beclin 1 is monoallelically deleted and is under-expressed.
I nb r a i nt u m o r s ,B e c l i n1l e v e l sh a v eb e e nf o u n dt o
decrease with malignancy. In glioblastomas its expression is
reducedincomparison withlow-gradegliomas,andisrather
nuclear indicating a loss of gene function [34]. Our almost
negative ﬁndings in glioblastomas are consistent with these
observations and also with the high expression of pStat3
found in the same cases. In this regard, the induction of
autophagy by inhibitors of mTOR [35] and pStat3 [14], in
addition to radiation and chemotherapy with temozolomide
[36–38], may be signiﬁcant for therapeutic approaches.
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